New combo therapy shows promise for Hard-to-Treat cervical cancer
NCT ID NCT03614949
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether adding targeted radiation (SBRT) to the immunotherapy drug atezolizumab can shrink tumors better than atezolizumab alone in people with cervical cancer that has come back or spread. About 21 adults with advanced cervical cancer are participating. The goal is to see if the combination improves the number of patients whose tumors shrink or disappear.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
-
Ohio State University - OSUMC - Wexner Medical Center
Hilliard, Ohio, 43026, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Pronged attack shrink Hard-to-Treat cancers?
- Could a genetic marker guide future cancer therapies in taiwan?
- AI takes on cancer radiotherapy: can a computer plan treatment in minutes?
- Could a lighter immunotherapy schedule keep advanced cancers in check?
- Protein-Wrapped chemo aims to hit tumors harder, spare healthy cells
- Can acupuncture help women regain bladder control after hysterectomy?